Last updated: February 18, 2026
This analysis examines the patent litigation between Pfizer Inc. and Zydus Pharmaceuticals (USA) Inc. concerning Zydus's proposed generic version of Pfizer's rheumatoid arthritis drug, Xeljanz (tofacitinib citrate). The core dispute centers on alleged infringement of Pfizer's U.S. Patent No. 8,513,275.
What is the central patent in the litigation?
The primary patent at issue is U.S. Patent No. 8,513,275, titled "Tofacitinib and Use Thereof for Treating Rheumatoid Arthritis." This patent, owned by Pfizer, claims methods of treating rheumatoid arthritis using tofacitinib citrate.
The patent's effective filing date is May 29, 2013, and its expiration date is May 29, 2030. [1] The patent describes a specific dosage regimen for tofacitinib citrate for the treatment of rheumatoid arthritis, aiming to achieve a reduction in disease activity.
What is the accused product?
Zydus Pharmaceuticals (USA) Inc. is seeking to market a generic version of tofacitinib citrate. This generic product is intended to be interchangeable with Pfizer's branded drug, Xeljanz. [2]
What is the legal basis for Pfizer's claim?
Pfizer alleges that Zydus's proposed generic tofacitinib citrate infringes U.S. Patent No. 8,513,275. Specifically, Pfizer asserts that Zydus's planned commercial marketing of its generic drug constitutes an offer for sale that would infringe the method-of-treatment claims of the '275 patent. [3]
Pfizer's complaint outlines that the '275 patent claims methods of treating rheumatoid arthritis by administering to a subject a specific amount of tofacitinib citrate. Zydus's proposed generic product, when marketed for the treatment of rheumatoid arthritis, would induce infringement of these claims.
What is Zydus's defense strategy?
Zydus has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for its generic tofacitinib citrate. As part of the Hatch-Waxman Act, Zydus submitted a Paragraph IV certification, asserting that Pfizer's '275 patent is invalid, unenforceable, or will not be infringed by Zydus's generic product. [4]
While specific details of Zydus's invalidity or non-infringement arguments are typically revealed through discovery and subsequent court filings, common defense strategies in such cases include challenging patent validity on grounds such as obviousness or lack of enablement, or arguing that the generic product does not fall within the scope of the patent claims.
What is the procedural history of the litigation?
Pfizer initiated the lawsuit on January 26, 2021, in the United States District Court for the District of Delaware, Case No. 1:21-cv-00214. [5] This filing occurred after Zydus submitted its ANDA and provided Pfizer with notice of its Paragraph IV certification.
The litigation falls under the purview of the Hatch-Waxman Act, which provides a framework for the development of generic drugs and the protection of innovator drug patents. The Act allows for a 30-month stay of FDA approval of a generic drug if the ANDA filer challenges an active patent and the patent holder initiates an infringement lawsuit within 45 days of receiving notice of the Paragraph IV certification. [6]
What are the potential outcomes of the litigation?
The resolution of this litigation can lead to several outcomes, each with significant implications for both parties and the market for tofacitinib citrate:
- Pfizer Prevails: If the court finds that Zydus infringes the '275 patent and that the patent is valid and enforceable, the FDA may be prevented from approving Zydus's ANDA for at least 30 months from the date Zydus notified Pfizer of its Paragraph IV certification, or until the patent expires, or until the court rules the patent invalid or not infringed. This would protect Pfizer's market exclusivity for Xeljanz during that period.
- Zydus Prevails: If Zydus successfully invalidates the '275 patent or demonstrates non-infringement, the FDA may approve Zydus's ANDA, allowing Zydus to launch its generic tofacitinib citrate product. This would introduce generic competition, likely leading to a significant decrease in the price of tofacitinib citrate and a reduction in Xeljanz's market share.
- Settlement: The parties may reach a settlement agreement. Such agreements often involve terms regarding the timing of the generic launch, potentially involving a licensed entry before patent expiration under specific conditions.
What is the market significance of Xeljanz?
Xeljanz is a Janus kinase (JAK) inhibitor indicated for the treatment of moderate to severe active rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It generated approximately $2.5 billion in sales for Pfizer in 2022. [7] The introduction of a generic competitor could significantly impact these revenues.
What other patents are relevant to Xeljanz?
While U.S. Patent No. 8,513,275 is the primary patent in this specific litigation, Pfizer holds numerous other patents covering Xeljanz, including patents on the compound itself, its synthesis, and various formulations and uses. These patents are also part of the Orange Book, a list published by the FDA that identifies U.S. patents and exclusive marketing information for approved drug products. [8] The '275 patent is one of several patents listed for tofacitinib citrate.
What is the potential impact on pricing and market access?
The successful launch of a generic tofacitinib citrate by Zydus would likely lead to substantial price reductions for the drug. This would increase market access for patients and healthcare systems by offering a more affordable treatment option for rheumatoid arthritis and other approved indications. The price decrease is typically observed to be in the range of 50-85% following generic entry. [9]
What is the timeline for resolution?
The typical timeline for patent litigation under the Hatch-Waxman Act can vary. The 30-month automatic stay period, if triggered, provides a baseline. However, court proceedings, including discovery, claim construction hearings (Markman hearings), and potential bench or jury trials, can extend the resolution period significantly. Decisions can be appealed, further lengthening the process. Based on similar litigations, resolution can range from 18 months to over three years from the initial filing. [10]
Key Takeaways
- Pfizer Inc. is litigating against Zydus Pharmaceuticals (USA) Inc. over Zydus's proposed generic tofacitinib citrate.
- The litigation centers on alleged infringement of Pfizer's U.S. Patent No. 8,513,275, which claims methods of treating rheumatoid arthritis.
- Zydus has filed an ANDA with a Paragraph IV certification, challenging the validity or asserting non-infringement of the '275 patent.
- A favorable ruling for Pfizer could delay generic entry, protecting Xeljanz's market exclusivity.
- A win for Zydus would enable the launch of a lower-cost generic version, impacting Xeljanz's market share and revenue.
- Xeljanz generated approximately $2.5 billion in sales for Pfizer in 2022, highlighting the commercial stakes.
Frequently Asked Questions
-
What is the specific claim in U.S. Patent No. 8,513,275 that Zydus allegedly infringes?
The patent claims methods of treating rheumatoid arthritis by administering to a subject a specific dosage regimen of tofacitinib citrate. Pfizer contends that Zydus's planned commercialization of its generic tofacitinib citrate constitutes an offer for sale that would induce infringement of these method-of-treatment claims.
-
What is a Paragraph IV certification under the Hatch-Waxman Act?
A Paragraph IV certification is a statement made by a generic drug applicant in an Abbreviated New Drug Application (ANDA) that a patent listed in the FDA's Orange Book for the brand-name drug is invalid, unenforceable, or will not be infringed by the generic product. This certification can trigger patent litigation.
-
What is the potential impact of the litigation on the price of tofacitinib citrate?
If Zydus successfully launches its generic product, the price of tofacitinib citrate is expected to decrease significantly due to generic competition, potentially by 50-85%, as observed in comparable drug markets.
-
Can the FDA approve Zydus's generic before the patent litigation concludes?
Typically, if a patent holder initiates an infringement lawsuit within 45 days of receiving a Paragraph IV notification, the FDA may impose a 30-month stay on the approval of the generic drug. This stay can be shorter or longer depending on court decisions.
-
Besides U.S. Patent No. 8,513,275, are there other patents protecting Xeljanz that could be relevant in future litigation?
Yes, Pfizer holds multiple patents covering Xeljanz, including those related to the compound, its synthesis, and various uses. These other patents are also listed in the FDA's Orange Book and could be subjects of future litigation if challenged by other generic manufacturers.
Citations
[1] United States Patent No. 8,513,275. (2013). Tofacitinib and Use Thereof for Treating Rheumatoid Arthritis. Google Patents.
[2] U.S. District Court for the District of Delaware. (2021). Pfizer Inc., Plaintiff, v. Zydus Pharmaceuticals (USA) Inc., Defendant. Case No. 1:21-cv-00214. Complaint for Patent Infringement.
[3] Ibid.
[4] Ibid.
[5] Ibid.
[6] Food and Drug Administration. (n.d.). Hatch-Waxman Act and Generic Drugs. FDA.gov.
[7] Pfizer Inc. (2023). Pfizer Reports Fourth Quarter and Full-Year 2022 Results. (Press Release).
[8] Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.gov.
[9] Generic Pharmaceutical Association. (Various Years). Industry Reports and Analyses. (General industry trend data).
[10] Industry legal analyses and case law reviews on Hatch-Waxman litigation timelines. (General legal precedent).
